CQDM welcomes Zymeworks as a new member of CQDM’s biopharmaceutical consortium

News & Events

Montreal, February 27, 2020 – CQDM is pleased to welcome Zymeworks Inc. as a new member of its biopharmaceutical research consortium established to identify and invest in highly innovative biopharmaceutical research projects in Quebec and Canada with the ultimate goal of enabling the development of better treatments for patients. As a CQDM member, Zymeworks will benefit from the consortium’s ability … Read More

2nd Annual Gordon Shore Prize – Postdoctoral Internships in the Biopharmaceutical Industry

News & Events

Presented by CQDM, Diazon Pharmaceuticals and Mitacs, the Gordon Shore Prize is awarded to new graduates whose doctoral thesis demonstrated their research excellence in the life science field. A 6-month postdoctoral internship of $24,000 will be offered to each of the awardees by the participating Quebec-based companies: Feldan Therapeutics, Kisoji Biotechnology, Ovensa Innovations and Repare Therapeutics. To be eligible, candidates … Read More

We are recruiting! Interested in a Controller – finance & administration position? Apply now!

Job offers, News & Events

Controller – finance & administration ABOUT CQDM  Since its creation, CQDM has raised nearly $100 million to fund the development of approximately 80 outstanding technologies addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective drugs. … Read More

Project funded through CQDM will explore potential of Fusion Genomics’ ONETest™ to improve diagnosis of respiratory tract infections

News & Events

We’re delighted to announce that Fusion Genomics has been awarded $1 million to conduct a prospective clinical study evaluating its product: ONETest™. The project will be funded through our Quantum Leap program with support from Merck and will explore the improvement for diagnosis of respiratory tract infections. Fusion Genomics ONETest™ is a highly sensitive, cost-effective next-generating sequencing-based assay capable of … Read More

CQDM and the Canadian Cancer Society commend Theratechnologies and UQAM for their success in developing a new therapy against the most aggressive form of breast cancer

News & Events

Montréal, December 18, 2019 – CQDM congratulates Theratechnologies for reporting positive results on TH-1902, a docetaxel conjugate for the treatment of triple-negative breast cancer (TNBC), during the prestigious San Antonio Breast Cancer Symposium held on December 10-14 in San Antonio (Texas, USA). Theratechnologies also announced that the Food and Drug Administration (FDA) has approved the launch of the Phase 1 clinical … Read More

2nd Annual Gordon Shore Prize – Call for Proposal to Private Companies

News & Events

Private companies based in Quebec with biopharmaceutical-related activities are invited to propose postdoctoral internship positions for new doctoral graduates, future awardees of the Gordon Shore Prize. Award sponsors, CQDM, Diazon Pharmaceuticals and Mitacs will finance 50% of these postdoctoral internships. The company must agree to pay the other half of the new graduate’s salary. The application and the obtaining of the … Read More

Bernard Massie and Cameron Black appointed to CQDM’s Scientific Advisory Board

News & Events

Montreal, November 29, 2019 – The Chairman of the Scientific Advisory Board, Daniel Hétu, and the President and CEO of CQDM, Diane Gosselin, are pleased to announce the appointment of two new members to CQDM’s governance. Bernard Massie, former Director General, Human Health Therapeutics at the NRC, and Cameron Black, Executive Vice President, Discovery at Repare Therapeutics will be joining CQDM’s Scientific … Read More

The project led by Michel Bouvier and Domain Therapeutics with the support of CQDM is awarded the RSRI Recognition Award at the ADRIQ Innovation Prize Gala

News & Events

The project led by Michel Bouvier and Domain Therapeutics with the support of CQDM is awarded the RSRI Recognition Award at the ADRIQ Innovation Prize Gala Montreal, November 22, 2019 – CQDM is proud to announce that the project led by Michel Bouvier from the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and the biotech Domain … Read More

Zealand Pharma’s acquisition of Encycle Therapeutics highlights the impact of CQDM’s early support

News & Events

Zealand Pharma’s acquisition of Encycle Therapeutics highlights the impact of CQDM’s early support on Canadian biotech company creation and success. Montreal, November 11th, 2019 – CQDM commends Encycle Therapeutics for their acquisition by Zealand Pharma (NASDAQ: ZEAL)[1]. CQDM is proud to have supported Encycle Therapeutics and its technology platform from the very beginning in partnership with Toronto Innovation Acceleration Partnership … Read More